Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $1,539,939.37 in Stock

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 11,699 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the sale, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Merck & Co., Inc. Stock Up 0.2%

Shares of NYSE MRK opened at $135.78 on Friday. The business has a 50-day moving average of $125.54 and a two-hundred day moving average of $119.94. The company has a market capitalization of $334.98 billion, a price-to-earnings ratio of 108.62, a price-to-earnings-growth ratio of 5.85 and a beta of 0.19. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.97. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the prior year, the business posted $2.13 EPS. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MRK. CICC Research assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price objective on the stock. Bank of America upped their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Barclays increased their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.50.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.